A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia

키워드

참고문헌 (122)

1. Tandon R, "Schizophrenia,"just the facts" what we know in 2008. 2. Epidemiologyand etiology", Schizophr Res, 102, pp.1~18 (2008)
2. Tandon R, "Schizophrenia,"just the facts" 4. Clinical features and conceptualization", Schizophr Res, 110, pp.1~23 (2009)
3. Wong AH, "Schizophrenia: from phenomenology to neurobiology", Neurosci Biobehav Rev, 27, pp.269~306 (2003)
4. van Os J, "Schizophrenia", Lancet, 374, pp.635~645 (2009)
5. Keshavan MS, "Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology", Schizophr Res, 106, pp.89~107 (2008)
6. Buckley PF, "Brain-derived neurotrophic factor: findings in schizophrenia", Curr Opin Psychiatry, 24, pp.122~127 (2011)
7. Balaratnasingam S, "Brain Derived Neurotrophic Factor: a novel neurotrophin involved in psychiatric and neurological disorders", Pharmacol Ther, 134, pp.116~124 (2012)
8. Favalli G, "The role of BDNF in the pathophysiology and treatment of schizophrenia", J Psychiatr Res, 46, pp.1~11 (2012)
9. Barde YA, "Purification of a new neurotrophic factor from mammalian brain", EMBO J, 1, pp.549~553 (1982)
10. Lu B, "Cell biology of BDNF and its relevance to schizophrenia", Novartis Found Symp, 289, pp.119~129 (2008)
11. Binder DK, "Brain-derived neurotrophic factor, In Encyclopedia of hormones", pp.209~214 (2003), Academic press
12. Thoenen H., "The changing scene of neurotrophic factors", Trends Neurosci, 14, pp.165~170 (1991)
13. Aid T, "Mouse and rat BDNF gene structure and expression revisited", J Neurosci Res, 85, pp.525~535 (2007)
14. Numakawa T, "BDNF function and intracellular signaling in neurons", Histol Histopathol, 25, pp.237~258 (2010)
15. Martinowich K, "Interaction between BDNF and serotonin: role in mood disorders", Neuropsychopharmacology, 33, pp.73~83 (2008)
16. Lu Y, "BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory?", Neurobiol Learn Mem, 89, pp.312~323 (2008)
17. Shoval G, "The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia", Eur Neuropsychopharmacol, 15, pp.319~329 (2005)
18. Lipsky RH, "Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity", Ann N Y Acad Sci, 1122, pp.130~143 (2007)
19. Nanko S, "Brain-derived neurotrophic factor gene and schizophrenia: polymorphism screening and association analysis", Schizophr Res, 62, pp.281~283 (2003)
20. Szekeres G, "The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia", Schizophr Res, 65, pp.15~18 (2003)
21. Jö~nsson EG, "Brain-derived neurotrophic factor gene (BDNF) variants and schizophrenia: an association study", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.924~933 (2006)
22. Xu MQ, "Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: a moderate-scale population-based study and meta-analysis", Schizophr Res, 91, pp.6~13 (2007)
23. Kawashima K, "BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis", Schizophr Res, 112, pp.72~79 (2009)
24. Yi Z, "Lack of effect of brain derived neurotrophic factor (BDNF) Val66Met polymorphism on early onset schizophrenia in Chinese Han population", Brain Res, 1417, pp.146~150 (2011)
25. Zakharyan R, "Functional variants of the genes involved in neurodevelopment and susceptibility to schizophrenia in an Armenian population", Hum Immunol, 72, pp.746~748 (2011)
26. Zintzaras E., "Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis", Psychiatr Genet, 17, pp.69~75 (2007)
27. Watanabe Y, "Metaanalysis of case-control association studies between the C270T polymorphism of the brain-derived neurotrophic factor gene and schizophrenia", Schizophr Res, 95, pp.250~252 (2007)
28. Hajek T, "Reduced hippocampal volumes in healthy carriers of brain-derived neurotrophic factor Val66Met polymorphism: meta-analysis", World J Biol Psychiatry, 13, pp.178~187 (2012)
29. Takahashi T, "Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons", Neurosci Lett, 435, pp.34~39 (2008)
30. Egan MF, "The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function", Cell, 112, pp.257~269 (2003)
31. Hong CJ, "Effects of BDNF polymorphisms on brain function and behavior in health and disease", Brain Res Bull, 86, pp.287~297 (2011)
32. Pivac N, "Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.356~362 (2011)
33. Zhang XY, "BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia", Neuropsychopharmacology, 33, pp.2200~2205 (2008)
34. Spalletta G, "BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia", Eur Psychiatry, 25, pp.311~313 (2010)
35. Thompson Ray M, "Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders", J Psychiatry Neurosci, 36, pp.195~203 (2011)
36. Vasic N, "Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?", Eur Arch Psychiatry Clin Neurosci (2011)
37. Issa G, "An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies", Neurobiol Dis, 39, pp.327~333 (2010)
38. Pan W, "Transport of brain-derived neurotrophic factor across the bloodbrain barrier", Neuropharmacology, 37, pp.1553~1561 (1998)
39. Klein AB, "Blood BDNF concentrations reflect brain-tissue BDNF levels across species", Int J Neuropsychopharmacol, 14, pp.347~353 (2011)
40. Chen D, "Decreased levels of serum brain-derived neurotrophic factor in drug-naï�ve first-episode schizophrenia: relationship to clinical phenotypes", Psychopharmacology, 207, pp.375~380 (2009)
41. Rizos EN, "Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients", Schizophr Res, 129, pp.201~204 (2011)
42. Pirildar S, "Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment", Prog Neuropsychopharmacol Biol Psychiatry, 28, pp.709~713 (2004)
43. Vinogradov S, "Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?", Biol Psychiatry, 66, pp.549~553 (2009)
44. Zhang XY, "Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics", J Psychiatr Res, 41, pp.997~1004 (2007)
45. Xiu MH, "Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.1508~1512 (2009)
46. Tan YL, "Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics", Neurosci Lett, 382, pp.27~32 (2005)
47. Green MJ, "Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis", Mol Psychiatry, 16, pp.960~972 (2011)
48. Carlino D, "Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia", J Psychiatr Res, 45, pp.273~279 (2011)
49. Angelucci F, "Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration", J Neurosci Res, 60, pp.783~794 (2000)
50. Chlan-Fourney J, "Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration", Brain Res, 954, pp.11~20 (2002)
51. Zhang XY, "Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology", Schizophr Res, 57, pp.247~258 (2002)
52. Pedrini M, "Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation", Neurosci Lett, 491, pp.207~210 (2011)
53. Yang YQ, "Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia", Neurosci Lett, 502, pp.37~40 (2011)
54. Liou YJ, "Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients", Neuromolecular Med, 5, pp.243~251 (2004)
55. Carlsson A, "Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications", Life Sci, 61, pp.75~94 (1997)
56. Sokoloff P, "Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders", Neurotox Res, 4, pp.671~678 (2002)
57. Guillin O, "Brain-derived neurotro phic factor in schizophrenia and its relation with dopamine", Int Rev Neurobiol, 78, pp.377~395 (2007)
58. Hasbi A, "Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth", Proc Natl Acad Sci U S A, 106, pp.21377~21382 (2009)
59. Djalali S, "Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development", J Neurochem, 92, pp.616~627 (2005)
60. Lyons WE, "Brain-derived neurotrophic factordeficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities", Proc Natl Acad Sci U S A, 96, pp.15239~15244 (1999)
61. Celada P, "Local infusion of brain-derived neurotrophic factor modifies the firing pattern of dorsal raphéserotonergic neurons", Brain Res, 712, pp.293~298 (1996)
62. Lang UE, "Association of BDNF serum concentrations with central serotonergic activity: evidence from auditory signal processing", Neuropsychopharmacology, 30, pp.1148~1153 (2005)
63. Benes FM, "Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients", Arch Gen Psychiatry, 48, pp.996~1001 (1991)
64. Arnold SE, "Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions", Am J Psychiatry, 152, pp.738~748 (1995)
65. Zaidel DW, "Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia", Am J Psychiatry, 154, pp.812~818 (1997)
66. Blennow K, "Synaptic degeneration in thalamus in schizophrenia", Lancet, 348, pp.692~693 (1996)
67. Ernfors P, "Local and target-derived actions of neurotrophins during peripheral nervous system development", Cell Mol Life Sci, 58, pp.1036~1044 (2001)
68. McAllister AK., "Neurotrophins and neuronal differentiation in the central nervous system", Cell Mol Life Sci, 58, pp.1054~1060 (2001)
69. Lu B, "Regulation of neurogenesis by neurotrophins: implications in hippocampus-dependent memory", Neuron Glia Biol, 1, pp.377~384 (2004)
70. Mondelli V, "Stress and inflammation reduce brain- derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume", J Clin Psychiatry, 72, pp.1677~1684 (2011)
71. Smith GN, "Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis", Schizophr Res, 134, pp.253~259 (2012)
72. Steen RG, "Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies", Br J Psychiatry, 188, pp.510~518 (2006)
73. Ho BC, "Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia", Arch Gen Psychiatry, 68, pp.128~137 (2011)
74. Woods BT, "Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism", Am J Psychiatry, 155, pp.1661~1670 (1998)
75. Rapoport JL, "The neurodevelopmental model of schizophrenia: update 2005", Mol Psychiatry, 10, pp.434~449 (2005)
76. Lewis DA, "Schizophrenia as a disorder of neurodevelopment", Annu Rev Neurosci, 25, pp.409~432 (2002)
77. Murakami S, "Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly", Neurosci Res, 53, pp.129~139 (2005)
78. Roceri M, "Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions", Biol Psychiatry, 55, pp.708~714 (2004)
79. Elzinga BM, "The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met", Psychopharmacology, 214, pp.319~328 (2011)
80. Zhang XY, "Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia", Psychopharmacology (2012)
81. Rund BR, "A review of longitudinal studies of cognitive functions in schizophrenia patients", Schizophr Bull, 24, pp.425~435 (1998)
82. Green MF, "Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?", Schizophr Bull, 26, pp.119~136 (2000)
83. Gray J, "Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene", Diabetes, 55, pp.3366~3371 (2006)
84. Niitsu T, "Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.1836~1840 (2011)
85. Meyer JM, "The metabolic syndrome and schizophrenia", Acta Psychiatr Scand, 119, pp.4~14 (2009)
86. Bobes J, "Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort", Schizophr Res, 119, pp.101~109 (2010)
87. McCreadie RG, "Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study", Br J Psychiatry, 183, pp.534~539 (2003)
88. Wang J, "The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns", Eur Heart J, 28, pp.857~864 (2007)
89. Simons LA, "Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo study", Heart Lung Circ, 20, pp.214~219 (2011)
90. de Simone G, "Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study", Nutr Metab Cardiovasc Dis, 19, pp.98~104 (2009)
91. Goff DC, "Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists", J Clin Psychiatry, 66, pp.183~194 (2005)
92. Brown S, "Twenty-five year mortality of a community cohort with schizophrenia", Br J Psychiatry, 196, pp.116~121 (2010)
93. Auquier P, "Mortality in schizophrenia", Pharmacoepidemiol Drug Saf, 16, pp.1308~1312 (2007)
94. Kernie SG, "BDNF regulates eating behavior and locomotor activity in mice", EMBO J, 19, pp.1290~1300 (2000)
95. Lebrun B, "Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview", Auton Neurosci, 126, pp.30~38 (2006)
96. Rosas-Vargas H, "Brain-derived neurotrophic factor, food intake regulation, and obesity", Arch Med Res, 42, pp.482~494 (2011)
97. Golden E, "Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging", PLoS One, 5, pp.e10099~ (2010)
98. Chaldakov G, "The metabotrophic NGF and BDNF: an emerging concept", Arch Ital Biol, 149, pp.257~263 (2011)
99. Chaldakov GN, "Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease?", Prog Brain Res, 146, pp.279~289 (2004)
100. Saetre P, "Inflammation-related genes up-regulated in schizophrenia brains", BMC Psychiatry, 7, pp.46~ (2007)
101. Fan X, "Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia", Schizophr Res, 118, pp.211~217 (2010)
102. Fan X, "Inflammation and schizophrenia", Expert Rev Neurother, 7, pp.789~796 (2007)
103. Theodoropoulou S, "Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients", Schizophr Res, 47, pp.13~25 (2001)
104. Potvin S, "Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review", Biol Psychiatry, 63, pp.801~808 (2008)
105. Suvisaari J, "Inflammation in psychotic disorders: a populationbased study", Psychiatry Res, 189, pp.305~311 (2011)
106. Miller BJ, "Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects", Biol Psychiatry, 70, pp.663~671 (2011)
107. Altamura AC, "HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment", Eur Neuropsychopharmacol, 10, pp.1~4 (1999)
108. Maino K, "T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment", Psychiatry Res, 152, pp.173~180 (2007)
109. Riedel M, "Decreased T cellular immune response in schizophrenic patients", J Psychiatr Res, 41, pp.3~7 (2007)
110. Rothermundt M, "Review of immunological and immunopathological findings in schizophrenia", Brain Behav Immun, 15, pp.319~339 (2001)
111. Yang Y, "Altered levels of acute phase proteins in the plasma of patients with schizophrenia", Anal Chem, 78, pp.3571~3576 (2006)
112. Monji A, "Cytokines and schizophrenia: Microglia hypothesis of schizophrenia", Psychiatry Clin Neurosci, 63, pp.257~265 (2009)
113. Braun A, "Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation", Am J Respir Cell Mol Biol, 21, pp.537~546 (1999)
114. Kerschensteiner M, "Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?", J Exp Med, 189, pp.865~870 (1999)
115. Kerschensteiner M, "Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases", Ann Neurol, 53, pp.292~304 (2003)
116. Gureje O, "Gender and schizophrenia: association of age at onset with antecedent, clinical and outcome features", Aust N Z J Psychiatry, 32, pp.415~423 (1998)
117. Castle D, "Differences in distribution of ages of onset in males and females with schizophrenia", Schizophr Res, 33, pp.179~183 (1998)
118. Riecher-Rössler A, "Estrogens and gonadal function in schizophrenia and related psychoses, In Biological basis of sex differences in psychopharmacology", pp.155~171 (2011), Springer
119. Wong J, "Increases in Two Truncated TrkB Isoforms in the Prefrontal Cortex of People With Schizophrenia", Schizophr Bull (2011)
120. Sohrabji F, "Estrogen-BDNF interactions: implications for neurodegenerative diseases", Front Neuroendocrinol, 27, pp.404~414 (2006)
121. Solum DT, "Estrogen regulates the development of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus", J Neurosci, 22, pp.2650~2659 (2002)
122. Gibbs RB., "Treatment with estrogen and progesterone affects relative levels of brain-derived neurotrophic factor mRNA and protein in different regions of the adult rat brain", Brain Res, 844, pp.20~27 (1999)

관련 논문AI추천